Shield for the vulnerable: antibody shots tested to block COVID in Immune-Weakened patients

NCT ID NCT05074433

Terminated Prevention Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested whether regular injections of lab-made antibodies (casirivimab+imdevimab) could prevent symptomatic COVID-19 in people with weakened immune systems. It involved 66 participants who were vaccinated but had a poor antibody response or couldn't get vaccinated. The trial was terminated early, and its main goal was to see if these injections provided better protection than a placebo.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Altoona Center for Clinical Research

Duncansville, Pennsylvania, 16635, United States
AppleMed Research Group, LLC

Miami, Florida, 33126, United States
Arthritis and Rheumatic Disease Specialties

Aventura, Florida, 33180, United States
Baptist Health Center for Clinical Research

Little Rock, Arkansas, 72205, United States
Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Burke Primary Care

Morganton, North Carolina, 28655, United States
Cedars-Sinai Medical Center

Los Angeles, California, 90048, United States
Central Alabama Research

Birmingham, Alabama, 35205, United States
Central Texas Clinical Research

Austin, Texas, 78705, United States
De La Cruz Research Center, LLC

Miami, Florida, 33184, United States
Elixia COVID-19

Hollywood, Florida, 33024, United States
Florida Medical Clinic, LLC

Zephyrhills, Florida, 33542, United States
Fred Hutchinson Cancer Research Center

Seattle, Washington, 98109, United States
Gabrail Cancer Center Research

Canton, Ohio, 44718, United States
Georgetown University

Washington D.C., District of Columbia, 20007, United States
Great Lakes Clinical Trials - Ravenswood

Chicago, Illinois, 60625, United States
Holy Name

Teaneck, New Jersey, 07666, United States
Houston Methodist Hospital

Houston, Texas, 77030, United States
Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
Innovative Research of West Florida, Inc.

Clearwater, Florida, 33756, United States
Institute of Human Virology

Baltimore, Maryland, 21201, United States
James R Berenson MD Inc.

West Hollywood, California, 90069, United States
Jersey Shore University Medical Center

Neptune City, New Jersey, 07753, United States
Johns Hopkins Hospital

Baltimore, Maryland, 21287, United States
Laboratory of Clinical Immunology and Microbiology, NIAID

Bethesda, Maryland, 20892, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Maimonides Cancer Center

Brooklyn, New York, 11220, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Miami Valley Hospital

Dayton, Ohio, 45409, United States
Midway Immunology and Research Center

Ft. Pierce, Florida, 34982, United States
Montefiore Medical Center

The Bronx, New York, 10467, United States
Penn Prevention Clinical Research Site

Philadelphia, Pennsylvania, 19104, United States
PharmaTex Research, LLC

Amarillo, Texas, 79109, United States
Regeneron Study Site

Long Beach, California, 90806, United States
Regeneron Study Site

Los Angeles, California, 90033, United States
Regeneron Study Site

Stanford, California, 94305, United States
Regeneron Study Site

North Haven, Connecticut, 06473-2195, United States
Regeneron Study Site

Atlanta, Georgia, 30322, United States
Regeneron Study Site

Marietta, Georgia, 30060, United States
Regeneron Study Site

Boston, Massachusetts, 02115, United States
Regeneron Study Site

New York, New York, 10032-3729, United States
Regeneron Study Site

Rochester, New York, 14642, United States
Regeneron Study Site

Syracuse, New York, 13210, United States
Regeneron Study Site

Cleveland, Ohio, 44195, United States
Regeneron Study Site

Providence, Rhode Island, 02903, United States
Regeneron Study Site

Richmond, Virginia, 23219, United States
Regeneron Study Site

Seattle, Washington, 98109, United States
Regeneron Study Site

Cuauhtémoc, Mexico City, 6700, Mexico
Regeneron Study Site 2

New York, New York, 10065, United States
SUNY Upstate Medical University

Syracuse, New York, 13215, United States
Spectrum Health

Grand Rapids, Michigan, 49503, United States
Stanford University

Palo Alto, California, 94304, United States
Swedish Medical Center- First Hill

Seattle, Washington, 98122, United States
Synergy Group Medical,LLC

Houston, Texas, 77087, United States
Temple University

Philadelphia, Pennsylvania, 19140, United States
Therapeutic Concepts, PA

Houston, Texas, 77004, United States
Tufts Medical Center

Boston, Massachusetts, 02111, United States
Tulane University

New Orleans, Louisiana, 70112, United States
University Of Colorado

Aurora, Colorado, 80045, United States
University of California

Sacramento, California, 95817, United States
University of Iowa

Iowa City, Iowa, 52242, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States
University of South Florida

Tampa, Florida, 33606, United States
University of Wisconsin - Madison

Madison, Wisconsin, 53792, United States
West Tennessee Research Institute

Jackson, Tennessee, 38305, United States

Conditions

Explore the condition pages connected to this study.

IMMUNOCOMPROMISED